Trials Sponsors Conditions Drugs Pricing

Conditions

Kidney Transplant; Complications Surgery

Outcome Measures

Primary Outcomes (3)

Enrollment
\>40% of eligible participants enroll (4/month) would allow us to complete a fully powered (n=312) patient trial in 24 months.
One month
Adequate pro-hab program adherence
\>75% adherence is required to meaningfully benefit from multimodal health-promotion interventions.
A minimum of 4 weeks before surgery and 18 weeks after discharged from surgery
Adequate patient-reported outcome follow up
\>90% complete outcome ascertainment ensures a low risk of bias trial in terms of non-missing data
One year

Study Arms (1)

Intervention (Pro-hab)

EXPERIMENTAL

The intervention is a multimodal pro-hab program delivered for at least 4 weeks prior to transplant and for 18 weeks after discharge from transplant surgery. The program will be supported virtually using an established, non-commercial platform available on computer, tablet or smartphone.

Behavioral: Pro-hab program

Interventions

Pro-hab programBehavioral

Multimodal pro-hab program delivered for at least 4 weeks prior to transplant and for 18 weeks after discharge from transplant, including exercise, breathing, nutrition, and psychosocial support.

Intervention (Pro-hab)

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Age ≥18 years
Scheduled, or on the pathway, for kidney transplant surgery

Sponsors & Collaborators

University of Ottawa Anesthesiology and Pain Medicine
Type not reportedcollaborator
OHRI ELEVATE Kidney Team Grants Competition
Type not reportedcollaborator

Study Sites (1)

The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada

Emily Hladkowicz, PhDCONTACT613-798-5555 ext. 18629 emhladkowicz@toh.ca

Daniel McIsaac, MDPRINCIPAL INVESTIGATOR

Study Officials

Daniel McIsaac, MD
The Ottawa Hospital
PRINCIPAL INVESTIGATOR

Central Study Contacts

Daniel McIsaac, MD

CONTACT

613-798-5555 dmcisaac@toh.ca

Emily Hladkowicz, PhD

CONTACT

613-798-5555

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 6, 2026

First Posted

July 10, 2026

Study Start

January 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

January 2028

Estimated

The PROAKTIVE Trial

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Study Arms (1)

Intervention (Pro-hab)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Study Arms (1)

Intervention (Pro-hab)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations